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ABSTRACT
DNA methylation is a key regulator of gene tran-
scription. Alterations in DNA methylation patterns
are common in most cancers, occur early in carci-
nogenesis and can be detected in body fluids.
Reliable and sensitive quantitative assays are
required to improve the diagnostic role of methyla-
tion in the management of cancer patients. Here we
present an optimized procedure, based on differen-
tial-high resolution melting analysis (D-HRMA), for
the rapid and accurate quantification of methylated
DNA. Two sets of primers are used in a single tube
for the simultaneous amplification of the methylated
(M) and unmethylated (Um) DNA sequences in
D-HRMA. After HRM, differential fluorescence was
calculated at the specific melting temperature after
automatic subtraction of UM-DNA fluorescence.
Quantification was calculated by interpolation on
an external standard curve generated by serial
dilutions of M-DNA. To optimize the protocol, nine
primer sets were accurately selected on the basis of
the number of CpG on promoters of hTERT and Bcl2
genes. The use of optimized D-HRMA allowed us to
detect up to 0.025% M-DNA. D-HRMA results of
DNA from 85 bladder cancers were comparable to
those obtained with real time quantitative methyla-
tion specific PCR. In addition, D-HRMA appears
suitable for rapid and efficient measurements in
‘in vitro’ experiments on methylation patterns after
treatment with demethylating drugs.
INTRODUCTION
Epigenetic modiﬁcations are deﬁned as heritable informa-
tion other than nucleotide sequence, including DNA
methylation and histone deacetylation. These mechanisms
can regulate a wide range of physiological and
pathological processes (1). DNA methylation occurs by
the covalent addition of a methyl group at the 50 of the
cytosine ring, resulting in 5-methylcytosine (2). In mam-
malian DNA, 5-methylcytosine is found in approximately
4% of genomic DNA, primarily at cytosine–guanosine
dinucleotides (CpGs). Such CpG sites are found more
frequently in small stretches of DNA, called CpG
islands. These islands are typically found in or near pro-
moter regions of genes (3). In contrast to the bulk of
genomic DNA, in which most CpG sites are heavily
methylated, CpG islands of normal somatic cells remain
unmethylated, allowing gene expression to occur (2).
Hypermethylation of CpG islands results in either down-
regulation or complete abrogation of gene-associated
expression, playing a role comparable to inactivating
mutations or deletions (1). Tumor suppressor genes,
genes encoding cell adhesion molecules and growth-
regulatory proteins, are often silenced in malignancies by
DNA hypermethylation (4). Promoter hypermethylation
can therefore constitute the initial hit in many cancers
(5). For these reasons the study of DNA methylation
shows great promise in the future management of cancer
patients. Potentially, DNA methylation should provide
relevant information in the classiﬁcation of tumors,
depending on their methylation status. Such classiﬁcation
might be of use in determining patient prognosis or poten-
tial response to therapy. However the most attractive
application of DNA methylation is probably as a speciﬁc
marker for the early detection of cancer. It is now clear
that aberrant DNA methylation is an early event in tumor
development and that hypermethylated sequences can be
detected in apparently normal epithelia largely before the
appearance of cancer (6). The development of PCR tech-
niques for the detection of methylated DNA, in particular
methylation-speciﬁc PCR (MSP) (7), has allowed methy-
lated sequences to be detected in human bioﬂuids contain-
ing small amounts of tumor-derived DNA, as recently
reviewed (8). However, to be used as a cancer marker,
DNA methylation requires ﬁne mapping and quantitative
determinations.
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tive assessment of DNA methylation [for details see (9)],
real time qPCR (quantitative methylation speciﬁc PCR:
qMSP) appears particularly suitable. As in traditional
qualitative MSP, the ﬁrst step of qMSP includes DNA
treatment with sodium bisulﬁte that generates diﬀerences
in methylation-dependent sequences at CpG dinucleo-
tides, by converting unmethylated cytosine residues to
uracil, while methylated cytosine is unmodiﬁed. The
methylation proﬁle of target sequences can then be
detected with primer sets and ﬂuorescent probes, speciﬁc
for methylated and unmethylated CpGs. The term
MethyLight (10) indicates a ﬂexible platform of possible
ﬂuorescence-based qMSP assays, determined by the alter-
native combinations of primer-probe sets speciﬁc for
methylated or unmethylated sequences.
High resolution melting (HRMA), an extension of
previous DNA dissociation or melting analysis, was
recently introduced as a technique for genotyping single-
nucleotide polymorphisms (11). This closed-tube method
is made possible by heteroduplex-detecting DNA dyes
that can be used at saturating concentrations without inhi-
biting PCR (12). These third generation ﬂuorescent
dsDNA dyes have low toxicity in an ampliﬁcation reaction
and can therefore be used at higher concentrations for
greater saturation of the dsDNA sample that collects ﬂu-
orescent signals with much greater optical and thermal
precision (11,12). There are already for HRMA several
applications in the diagnosis of human diseases (13).
Very recently HRMA was also proposed as a rapid and
sensitive technique for the assessment of DNA methyla-
tion (14,15) for the diagnosis of genetic imprinting disor-
ders (16,17), BRCA1 inactivation in breast cancer (18) and
MGMT and APC methylation in colorectal cancer (19).
Here we describe the optimization of a protocol for the
quantitative evaluation of DNA methylation based on the
diﬀerential analysis of ﬂuorescence during HRMA. Our
study focused on a preliminary test to determine the best
conditions for the assay on two diﬀerent genes: hTERT
that codiﬁes for the telomerase catalytic subunit and the
anti-apoptotic gene Bcl2. Both genes have been found to
be frequently methylated in bladder cancer (20). The opti-
mized protocols were then applied to the measurement in
biological samples and the results were compared with
those obtained with a MethyLight assay.
MATERIALS AND METHODS
Bladder cancer samples
A sample of fresh tumor tissue was obtained with a cold
cup biopsy forceps from 85 patients undergoing transure-
thral resection of bladder cancer. Tissue samples were
immediately steeped in RNAlater (Qiagen, Germany)
and stored according to the manufacturer’s instructions.
DNA was extracted by QIAamp DNA Mini Kit (Qiagen)
according to the manufacturer’s instructions.
Cell line
The adrenal cancer cell line H295R was cultured in
Ham’s-F12:DMEM (1:1) medium with ITS (insulin,
transferring and selenium), 2mM glutamine, antibiotics
and 10% fetal bovine serum in 5% CO2. Cells were treated
with the demethylating agent 5-Aza-20-deoxycytidine
(5-Aza) 24h after the seeding with a concentration of
5mM for 1, 3 and 6 days. Cells were collected and centri-
fuged at 10000 g at room temperature for 2min and
stored at –808C, until the DNA extraction. DNA was
extracted by QIAamp DNA Mini Kit (Qiagen) according
to the manufacturer’s instructions and stored at –808C.
DNA concentration was estimated with NanoDrop 1000
(NanoDrop Technologies).
Bisulfite treatment
DNA (500ng) obtained from cell lines or tissue samples
was submitted to bisulﬁte modiﬁcation using the EpiTect
Bisulﬁte Kit (Qiagen) following the manufacturer’s
protocol. Bisulﬁte-treated DNA was resuspended in 40ml
elution buﬀer and 1ml was used for D-HRMA and
MethyLight, respectively. For each experiment, CpG
Genome Universal Methylated and Unmethylated DNA
(Chemicon International Inc.) were used as positive
(100% methylated) and negative (0% methylated) con-
trols. After bisulﬁte treatment, DNA was immediately
submitted to D-HRMA and MethyLight analyses. Since
accurate quantiﬁcation of DNA after bisulﬁte treatment
was not possible due to its high degradation, the presence
of ampliﬁable DNA was tested by real time PCR using a
primer pair and a TaqMan
TM probe for the bisulﬁte con-
verted sequence of a non-CpG-containing region of
b-actin gene (see ‘MethyLight’ section for details), as pre-
viously described (20). All samples provided a correct
ampliﬁcation plot with a relatively constant Ct value of
26.0 3.1 (mean SD) and therefore were considered
suitable for D-HRMA and MethyLight assays. For
b-actin, the sequence of primers was (Forw) 50-TGGTG
ATGGAGGAGGTTTAGTAAGT and (Rev) 50-AACCA
ATAAAACCTACTCCTCCCTTAA, while TaqMan
probe was Fam-50-ACCACCACCCAACACACAATAA
CAAACACA.
hTERT and Bcl2 primers for HRMA
Analysis of the hTERT gene (Genebank: AF325900)
with MethylPrimer Express V1.0 software (Applied
Biosystems) revealed two CpG islands: island #1 from
 4771 to  4334 and island #2 from  2016 to  1151.
Island #2 was schematically divided into two sequences
(A from  2016 to  1532 and B from  1415 to 1151).
Three couples of primers were designed on sequence A
and three sets on sequence B, to generate amplicons
with a variable number of CpG dinucleotides.
Accordingly, primer pairs were named hTERT-3A,
hTERT-11A, hTERT-13A in sequence A and hTERT-
7B, hTERT-15B and hTERT-21B in sequence B, on the
basis of target sequence, CpG numbers and localization.
For each sequence we designed separated couples of pri-
mers for the methylated and unmethylated form, with
comparable annealing temperature. Primers sequences
and amplicon lengths are reported in Table 1.
For Bcl2 gene (Genebank: NM_000633) we identiﬁed a
single CpG island localized between the 50UTR and the
e86 Nucleic Acids Research,2009, Vol. 37,No. 12 PAGE2 OF10ﬁrst exon (from –1 to +263). In this sequence three
couples of primers were designed to generate amplicons
containing 7, 12 and 17 CpGs and indicated as Bcl2-7,
Bcl2-12 and Bcl2-17, respectively (Table 1).
All sets of primers for the methylated and unmethylated
forms were tested in separated MSP to verify ampliﬁcation
performances and to check their capacity to amplify selec-
tively the unmethylated and methylated sequences, respec-
tively (data not shown).
D-HRMA
HRMA was carried out on a Rotor-Gene
TM 6000
(Corbett Research). PCR was performed in 10ml vol-
ume containing 1  buﬀer, 1.5mM MgCl2, 1mM each
dNTPs, 300nM of each primer, 5mM of SYTO
9 (Invitrogen), 0.04U TaqGold (Applied Biosystems)
and 1ml of bisulﬁte modiﬁed DNA template. The ampli-
ﬁcation protocol was 15min at 958C, then 50 cycles of
30s at 958C, 30s at annealing temperature, 30s at
728C and a ﬁnal step of 30min at 728C. HRMA was
performed at 958C for 5min, 408C for 1min and with
a ramping from 658Ct o9 5 8C rising by 0.18C/s.
Melting curves were normalized using the HRMA soft-
ware before and after the major ﬂuorescence decrease.
A diﬀerential proﬁle was then evaluated for each sample
by comparing ﬂuorescence at the melting point against
the value of ﬂuorescence of the negative control
(unmethylated DNA). All experiments were performed
in duplicate.
Since reproducibility is an important issue in any
quantitative determination, we tested the intra- and
inter-assay variability of D-HRMA using three primers
sets (hTERT-3A, hTERT-7B and Bcl2-7) in three bladder
cancer samples carrying variable methylation levels. To
evaluate intra-assay reproducibility, 10 replicates of the
same bisulﬁte-treated DNAs were measured in a single
D-HRMA experiment. In addition, using the same
samples and primers, we repeated the measurement in
seven consecutive experiments to determine inter-assay
variability.
hTERT and Bcl2 MethylLight assays
MethyLight reaction was performed in 12.5ml ﬁnal
volume consisting in 1  quantiTect Probe PCR Master
Mix (Qiagen), 200mM of each probe, 600nM of forward
and reverse primers, 1ml of bisulﬁte-treated DNA. The
primers and probe sets were the same as previously
described (20). Ampliﬁcation was carried out at 958C for
10min, followed by 50 cycles at 958C for 15s, 608C for
1min in a Rotor-Gene
TM 3000 (Corbett Research). To
evaluate the percentage of methylation status, each
sample was normalized referring to a non-CpG containing
region of b-actin gene. The relative level of methylation
was determined by the 2
–Ct method (21), according
to the following formula in which Ct=unknown
sample (Cttarget gene –C t b-actin) – 100% methylated DNA
(Cttarget gene –C t b-actin).
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Linearity of D-HRMA
Linearity tests were performed by D-HRMA using the
nine primer sets. We prepared serial dilutions of methy-
lated and unmethylated DNA standards to create recon-
stituted samples with a constant DNA quantity (12.5ng)
but containing 100%, 50%, 25%, 6.25%, 1.56%, 0.4%,
0.1%, 0.025% and 0% methylated DNA. Each dilution
was then ampliﬁed with primer sets for hTERT and Bcl2
and submitted to D-HRMA, as previously described. The
obtained ampliﬁcation plots indicated that all dilutions
were ampliﬁed with comparable Ct values (Figure 1A).
Through the graph of normalized ﬂuorescence we
veriﬁed the HRMA proﬁle of the diﬀerent amplicons
(Figure 1B). Then a diﬀerential graph was generated by
normalizing each HRMA proﬁle against unmethylated
DNA (Figure 1C). The maximal height of the peak was
detected at the melting temperature of each ampliﬁcation
product. Diﬀerential analysis generated peaks with vari-
able height, due to the diﬀerence in ﬂuorescence between
unmethylated DNA and other dilutions. The highest peak
corresponded to the fully methylated DNA (100%).
The height of the other peaks decreased proportionally
in samples containing progressively lower methylation
percentages. Through the speciﬁc software it was possible
to extrapolate the value of diﬀerential ﬂuorescence peak
for each dilution (Figure 1D). These values were then plot-
ted against the dilution factor to generate a linear calibra-
tion curve (Figure 1E).
Performances of D-HRMA with different primer sets
HRMA was repeated with all primer sets for hTERT and
Bcl2 genes to compare the diﬀerent performances of the
assays in relation to the speciﬁc features of the amplicons
(i.e. length in bp and number of CpGs). To evidence
diﬀerences among primer sets, standard curves were gen-
erated plotting methylated DNA concentrations versus
the maximal height of diﬀerential peaks, at the respective
melting temperature. We found that all primer sets were
able to generate a linear dose–response even if with a
diﬀerential capacity to discriminate among percentages
of DNA methylation and with a diﬀerent operating
range. All the curves were compared for their slope, cor-
relation coeﬃcient and number of correctly ﬁtted points.
The slope of standard curves is the expression of the
proportionality between dose (percentage of methylated
DNA) and signal (diﬀerential of ﬂuorescence). In this
sense hTERT-3A primer set showed the best slope that
was nearly parallel to the ideal 458 angle and therefore
particularly suitable for accurate measurements. Unfortu-
nately, the relatively low number of CpGs ampliﬁed with
this primer set (seven CpGs: three in the internal ampliﬁed
sequence and four covered by the two primers) appeared
less sensitive in the detection of low levels of DNA methy-
lation, since 0.1% and 0.025% were not detectable. This
result seems to indicate that D-HRMA needs a major
number of modiﬁed CpGs to reach good levels of sensi-
tivity. Accordingly, when the hTERT-11A primer set
(11+4=15 total CpG) was used, we obtained a slight
reduction in the slope but an improvement in sensitivity,
since 0.025% methylated DNA was clearly distinguishable
from unmethylated DNA. When the number of ampliﬁ-
able CpGs was further increased with primer set hTERT-
13A (13+7=20 total CpGs), the slope tended to be
dramatically reduced with a consistent loss of discriminat-
ing capacity. In addition, the 0.025% concentration was
not detectable (Figure 2A–C).
To conﬁrm these ﬁndings and to exclude possible bias
due to DNA sequence, the experiment was repeated on
the other sequence (Sequence B) of the same gene.
Primer set hTERT-7B (7+7=14 total CpGs) had the
best slope and the maximal sensitivity in comparison to
hTERT-15B (15+5=10 total CpGs) and hTERT-21B
(21+6=27 total CpGs) primer sets (data not shown).
Finally, to exclude the possible gene-to-gene bias, we
repeated the same test using a sequence on the Bcl2
CpG island. The results indicated once again that the
best assay performances were obtained with primer sets
containing an intermediate number of CpG repeats. The
Bcl2-7 primer set (7+6=13 total CpGs) had cumula-
tively the best performance in comparison to Bcl2-12
(12+5=17 total CpGs) and Bcl2-17 (17+5=22 total
CpGs) (data not shown). All parameters of ﬁtting curves
obtained after D-HRMA with the diﬀerent primer sets
were reported in Table 2.
The number of CpGs, independently of the DNA
sequence, seems to inﬂuence the discriminative capacity
of each assay, represented by the slope of the respective
standard curves. As reported in Figure 3, the slope of the
standard curves generated by the nine primer sets is inver-
sely related to the number of total CpGs included in the
respective amplicon (Figure 3).
D-HRMA and bladder cancer methylation
After these preliminary assessments and to verify the accu-
racy of D-HRMA in quantifying the amount of methy-
lated DNA in unknown samples, we used all sets of
primers to determine the concentration of methylated
alleles in DNA extracted from 85 human bladder cancers.
Methylation was also measured in the same samples with a
conventional MethyLight method, based on real time
PCR and TaqMan probes. We evaluated the methylation
status with D-HRMA as percentage referring to a stan-
dard curve whereas MethyLight results were calculated as
relative quantiﬁcation with the 2
–Ct method (see
‘Material and Methods’ section for details).
Our data indicated that D-HRMA and MethyLight are
highly concordant when the best performing primer sets
(hTERT-3A, hTERT-7B and Bcl2-7) were used: taking
into account positive or negative samples with both meth-
ods, the agreement was 91% for hTERT-3A, 96% for
hTER-7B and 99% for Bcl2-7. The agreement between
D-HRMA and MethyLight was reinforced by the compar-
ability of numerical results obtained by the two methods
(Figure 4A–C). The use of other primer sets (hTERT-11,
hTERT-13, hTERT-15, hTERT-21) reduced dramatically
the correlation with MethyLight results (r=0.114,
r=0.358, r=0.122, r=0.379) (data not shown).
e86 Nucleic Acids Research,2009, Vol. 37,No. 12 PAGE4 OF10Reproducibility of D-HRMA
We calculated intra-assay variability as coeﬃcient of vari-
ation (%) at three diﬀerent levels of methylation and using
three primer sets (hTERT-3A, hTERT-7B and Bcl2-7).
In Table 3 we reported the mean methylation percentage,
its standard deviation and the coeﬃcient of variation.
According to methylation levels we found that intra-
assay variability ranged from 4.4% to 34%. Inter-assay
variability ranged from 7.4% to 48%.
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Figure 1. Example of the ﬂow chart for D-HRMA. (A) Ampliﬁcation plots of serial dilutions of methylated DNA (from 100% to 0%) were ampliﬁed
with primers for methylated and unmethylated forms (primer set hTERT-7B) in the same tubes. All the dilutions were ampliﬁed with comparable
ampliﬁcation plots (B) HRMA proﬁle of the same samples. (C) Fluorescence of each sample was normalized as diﬀerential signal against unmethy-
lated control. (D) Values of diﬀerential ﬂuorescence obtained at the melting temperature for each dilution. (E) Values of diﬀerential ﬂuorescence were
plotted against the percentage of methylation of each dilution to generate a typical standard curve. All the experiments were performed in duplicate.
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Figure 2. Diagrams of normalized ﬂuorescence of methylated DNA dilutions normalized against unmethylated control ﬂuorescence (left panels) and
corresponding plotted standard curve (right panels) for hTERT primer sets in sequence A of gene promoter (top: hTERT-3A; medium: hTERT-11A;
bottom: hTERT-13A). Slope and coeﬃcient of correlation were reported for each standard curve.
Table 2. Parameters of ﬁtting curves obtained after D-HRMA with the diﬀerent primer sets
Gene name and
sequence
Primer
sets
Linear
equation
Coeﬃcient of
correlation
Minimum detectable
percentage of methylated DNA (%)
hTERT Sequence A hTERT-3A Y=0.4740x   0.8460 0.9939 0.4
hTERT-11A Y=0.3029x+0.0114 0.9853 0.025
hTERT-13A Y=0.0852x+1.1250 0.9602 0.1
hTERT Sequence B hTERT-7B Y=0.2637x+0.2265 0.9828 0.025
hTERT-15B Y=0.1803x+0.7131 0.9289 0.1
hTERT-21B Y=0.1042x+1.0659 0.9889 0.4
Bcl2 Bcl2-7 Y=0.3727x   0.1966 0.9808 0.025
Bcl2-12 Y=0.2266x   0.0903 0.9126 0.025
Bcl2-17 Y=0.0281x+1.432 0.7899 0.1
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The accurate measurement of methylated DNA concen-
tration may also be useful when the eﬀect of a demethy-
lating agent is tested in ‘in vitro’ experiments. To test the
capacity of D-HRMA to measure slight variations in
DNA methylation in these experimental conditions, we
used the hTERT-3, hTERT-7 and Bcl2-7 primer sets to
verify the eﬀects of 5-Aza-2-deoxycytine treatment on the
human cell-line H295R in which hTERT and Bcl2 genes
were methylated. As reported in Figure 5, D-HRMA was
able to demonstrate the progressive demethylating eﬀects
by progressive reduction of Bcl2 methylated DNA in cel-
lular extracts. Similar results were obtained for hTERT
(data not shown).
DISCUSSION
DNA methylation appears to be a relevant biomarker in
the diagnosis of cancer. This epigenetic modiﬁcation has
potential advantages over genetic tests, since methylation
occurs widely throughout cancer cells and, in most cases,
always aﬀects the same promoter regions (22).
The introduction of highly sensitive techniques, such as
the qMSP has enhanced the clinical relevance of methyla-
tion studies. Quantitative techniques for the detection of
abnormal methylation patterns have potential advantages
for the correct use of methylated DNA as a cancer bio-
marker. First, aberrant DNA methylation of some genes
also occurs in non-malignant epithelia in physiological
and pathological conditions and tends to progressively
increase with age (23). Secondly, levels of DNA methyla-
tion may be related to tumor stage, grade and progression.
After the ﬁrst studies on the use of melting analysis to
detect methylated DNA (24,25), more recent papers have
demonstrated that HRMA can be a sensitive, easy and
inexpensive method to analyze DNA methylation
(14,15,19). However, in the set-up of the assay, strategies
for primer design can deeply inﬂuence the reliability of
HRMA for methylation studies. Primers can be designed
to overlap CpG dinucleotides or not. If primers anneal to
a sequence lacking in CpG, methylated and unmethylated
DNA is simultaneously ampliﬁed during PCR cycling and
HRMA can distinguish between them on the basis of
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Figure 4. Relationships between D-HRMA and MethyLight results in
DNA from 85 bladder cancers, using three primer-probe sets (from the
top, hTERT-3A, hTERT-7B and Bcl2-7). The levels of DNA methyla-
tion obtained by D-HRMA (y-axis) are reported as percentage of
methylated DNA whereas MethyLight results (x-axis) are expressed
as relative concentrations calculated with the 2
–Ct method (see
‘Materials and Methods’ section for details). Each sample was mea-
sured in duplicate. Note the logarithmic scale.
Figure 3. Inverse linear relationship between the number of CpGs in
sequences (for primers and internal sequences see Table 1) ampliﬁed by
the nine primer sets (x-axis) and the slope of standard curves generated
by serial dilutions of methylated DNA (y-axis). The number of CpGs,
independent of the DNA sequence, seems to inﬂuence the discrimina-
tive capacity of each assay, represented by the slope of respective stan-
dard curves (see Table 2 for values).
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but in most cases this primer design is not allowed by gene
sequence. In addition, preferential ampliﬁcation of one
allele cannot be excluded.
Wojdacz and Dobrovic (14) demonstrated that HRM
can provide a sensitive and linear assay for a high-
throughput assessment of methylation using a single
primer set, speciﬁc for methylated DNA, when annealing
temperature was chosen to amplify both methylated and
unmethylated DNA simultaneously. The main limitation
of this method is the bias deriving from the use a single
primer pair, which is expected to preferentially amplify
one of the two sequences (unmethylated/methylated).
This is a critical aspect, since even limited sample-to-
sample variations can deeply inﬂuence the reliability of
the assay. The problem appears even more important
when results from diﬀerent assay sessions must be
compared.
We tried to introduce a novel approach based on the use
of two sets of primers in a single tube, for the simultane-
ous ampliﬁcation of the methylated and unmethylated
forms of the same DNA sequence. Even if the homologous
primer pairs were chosen to have comparable annealing
temperatures, methylated and unmethylated DNA cannot
be proved to be ampliﬁed with similar eﬃciency. However,
at least in the best-performing primer sets, we can postu-
late that the single tube approach introduces a sort of
competitive ampliﬁcation between the two ampliﬁable tar-
gets that should maintain their reciprocal concentrations
constant across the ampliﬁcation. This improvement
seems to reduce the bias deriving from preferential ampli-
ﬁcation of unmethylated or unmethylated alleles, as
demonstrated by the consistency of our results.
After HRMA the two molecular forms of methylated
and unmethylated DNA can be distinguished through the
diﬀerent melting proﬁle. Quantiﬁcation was calculated
by interpolation on a standard curve generated with
serial dilution of methylated and unmethylated DNA.
For each concentration we plotted the height of diﬀeren-
tial peaks obtained after automatic subtraction of ﬂuores-
cence corresponding to unmethylated DNA. A similar
approach was used by Lorente et al. (26) who applied a
conventional melting analysis with SybrGreen, enabling
them to detect 5% methylated DNA. With the use of an
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Figure 5. Measurement of methylation status of Bcl2 gene in the adre-
nal cancer cell line H295R exposed to the demethylating agent 5-Aza-2-
deoxycitidine for 1, 3 and 6 days, using D-HRMA. (A) HRMA proﬁle
of DNA extracted from H295R cells on diﬀerent days of treatment and
control unmethylated (0%) DNA. (B) Fluorescence of each sample was
normalized as diﬀerential signal against unmethylated control.
(C) Percentage of DNA methylation in cells on diﬀerent days of treat-
ment. In this example, Bcl2-7 primer set was used. All the experiments
were performed in duplicate.
Table 3. Intra- and inter-assay variability of D-HMRA in three bladder cancer samples
Samples hTERT-3A hTERT-7B Bcl2-7
Intra-assay
a Inter-assay
b Intra-assay Inter-assay Intra-assay Inter-assay
Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV Mean SD CV
#1 57.1 16.4 28 60.1 19.9 33 88.2 14.3 16 86.7 18.7 21 0 – – 0 – –
#2 13.8 4.7 33 19.4 9.3 48 71.5 19.6 27 73.9 17.6 23 90.9 4.0 4.4 88.4 6.6 7.4
#3 2.0 0.7 35 3.3 1.3 41 64.5 11.8 18 62.4 16.6 26 93.9 4.0 4.3 93.0 11.2 12
Mean indicates mean percentage of DNA methylation measured by D-HRMA (%); SD: standard deviation of the mean; CV: coeﬃcient of
variation (%).
aIntra-assay variability was calculated in 10 replicates of three samples measured in the same experiment.
bInter-assay variability was calculated in three samples measured in seven diﬀerent assays.
e86 Nucleic Acids Research,2009, Vol. 37,No. 12 PAGE8 OF10optimized protocol of HRMA we were able to detect
0.025% methylated DNA in reconstituted samples. This
is a theoretical sensitivity, valuable for clinical studies.
The high levels of sensitivity are particularly important
when HRMA is used to detect traces of cancer DNA in
complex human matrices (blood, urine, stool, etc.).
In addition, since the amount of methylated DNA is not
predictable in an unknown sample, linearity should be
guaranteed in a wide range of possible concentrations.
For these reasons, we tried to optimize our test to satisfy
both these requirements.
Using diﬀerent genes and diﬀerent methylated
sequences, we tested the inﬂuence of CpG number as
amplicon length on HRMA performances. Our data
seem to indicate that the best proportionality between
methylated DNA and ﬂuorescence signal, as well as the
maximal sensitivity, are obtained when the number of
CpGs in amplicons is low. In the three sets of experiments,
our cumulative results indicated that a total of 13–15
CpGs in the ampliﬁed products guaranteed good linearity
and sensitivity. When the number of CpGs is lower, the
detection limit seems to get worse. Conversely, a higher
number of CpGs tends to reduce the slope and sensitivity
of the standard curve.
We cannot exclude that the length of amplicons may
inﬂuence D-HRMA performance, since a major number
of ampliﬁed CpGs are obviously connected to an increase
in the extent of amplicons. However, the big diﬀerences
in D-HRMA performances between amplicons of compa-
rable length (hTERT-3A versus hTERT-11A or hTERT-
11A versus hTERT-7B) seem to indicate that the
dimensions of PCR products are less relevant. Similarly,
the density of CpGs expressed as mean base pair per
CpG in ampliﬁed sequence, did not appear to inﬂuence
D-HRMA. A clear example emerged from the evaluation
of hTERT primer sets in sequence B of the promoter: the
three sets had the same CpG density (8.3, 8.8 and 8.6,
respectively) but showed very diﬀerent behavior.
In conclusion, our results seem to demonstrate that
HRM can directly provide a quantitative assay for esti-
mating the concentration of methylated DNA in any bio-
logical sample. We demonstrated that in standardized
conditions numerical data deriving from D-HRMA are
linear in a wide range of DNA methylation percentage.
Reproducibility and sensitivity of the assay are absolutely
compatible with a diagnostic use of the method. In addi-
tion, the use of best-performing sets of primers allowed the
accurate measurement of methylated DNA in bladder
cancer biopsies, as shown by the high levels of correlation
with data obtained with a quantitative reference method
like real time MethyLight. Finally, the use of an external
reference curve, generated by serial dilutions of methy-
lated DNA, is particularly relevant to keep under control
the experimental performances over the time. The evalu-
ation of reference parameters, like curve slope, its inter-
cept and coeﬃcient of correlation are parameters that can
monitor experimental variations between experiments.
In addition, D-HRMA appears suitable for rapid and eﬃ-
cient measurement in ‘in vitro’ experiments of modiﬁcation
of methylation patterns after treatments with demethylat-
ing drugs. However, the use of D-HRMA for quantitative
purposes requires an accurate optimization of the choice
of the best panel of primers to be used.
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